Targeting TOR dependence in cancer.
A challenge in cancer therapy has been to identify targets whose function is essential for survival of malignant cells but not normal cells. This Perspective discusses recent evidence that novel inhibitors of the kinase TOR can provide an unprecedented balance of anti-cancer efficacy and tolerability.
Janes
Matthew R
MR
Department of Molecular Biology & Biochemistry, University of California, Irvine, CA 92697, USA.
Fruman
David A
DA
D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D014157:Transcription Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000970:Antineoplastic Agents; C500984:CRTC1 protein, human; C493245:CRTC2 protein, human; D014157:Transcription Factors